The Journal of Practical Medicine >
The efficacy of pancreatic fluid molecular biomarkers for diagnosis of pancreatic cancer
Received date: 2024-02-21
Online published: 2024-11-19
Pancreatic cancer （PC） is one of the deadliest malignant tumors worldwide，known as the ‘king of cancers’ due to its insidious onset， high malignancy， and high mortality rate. PC is highly malignant and progresses rapidly， but its onset is insidious with atypical early symptoms， making it difficult to detect early lesions through conventional imaging studies. It is usually only discovered when symptoms like jaundice， abdominal and back pain occur. Surgical resection is currently the only curative option for PC. However， due to the difficulty in early diagnosis， the majority of patients are already in the middle to late stages at the time of diagnosis， missing the opportunity for surgery. Studies have confirmed that the progression of pancreatic cancer is relatively slow， with the initial tumor cells requiring at least 15 years to gain metastatic ability. Therefore， timely detection of pancreatic cancer through tumor markers could significantly improve the survival rate of patients. The most widely used and diagnostically valuable tumor marker in clinical practice is Carbohydrate antigen 199 （CA199）. However， due to about 3% ~ 7% of pancreatic cancer patients being Lewis antigen-negative blood types and not expressing CA19-9， its sensitivity is only 79% ~ 81%， which does not provide good efficacy for the diagnosis of pancreatic cancer. Pancreatic juice， as a fluid near the tumor， has attracted much attention as a good source of tumor-related biomarkers. Many studies have confirmed the accuracy of using proteins， DNA， and exosomes in pancreatic juice for the diagnosis of pancreatic cancer， showing great prospects for pancreatic juice as a source of tumor markers for the diagnosis of pancreatic cancer. Therefore， this thesis reviews the efficacy of pancreatic juice as a specimen for the diagnosis of pancreatic cancer.
Yu LIU , Li WANG , Bingfang CHEN , Kewen SUN , Yin. ZHANG . The efficacy of pancreatic fluid molecular biomarkers for diagnosis of pancreatic cancer[J]. The Journal of Practical Medicine, 2024 , 40(21) : 3101 -3106 . DOI: 10.3969/j.issn.1006-5725.2024.21.022
| 1 | GROSSBERG A J， CHU L C， DEIG C R， et al. Multidisciplinary standards of care and recent progress in pancreatic ductal adenocarcinoma ［J］. CA Cancer J Clin， 2020， 70（5）： 375-403. doi:10.3322/caac.21626 |
| 2 | HUANG J， LOK V， NGAI C H， et al. Worldwide Burden of， Risk Factors for， and Trends in Pancreatic Cancer ［J］. Gastroenterology， 2021， 160（3）： 744-754. doi:10.1053/j.gastro.2020.10.007 |
| 3 | ARNOLD M， ABNET C C， NEALE R E， et al. Global Burden of 5 Major Types of Gastrointestinal Cancer ［J］. Gastroenterology， 2020， 159（1）： 335-349. e15. doi:10.1053/j.gastro.2020.02.068 |
| 4 | CHARI S T. Detecting early pancreatic cancer： problems and prospects ［J］. Semin Oncol， 2007， 34（4）： 284-294. doi:10.1053/j.seminoncol.2007.05.005 |
| 5 | MIZRAHI J D， SURANA R， VALLE J W， et al. Pancreatic cancer ［J］. Lancet， 2020， 395（10242）： 2008-2020. doi:10.1016/s0140-6736(20)30974-0 |
| 6 | NAGAI K， KUWATANI M， HIRATA K， et al. Genetic Analyses of Cell-Free DNA in Pancreatic Juice or Bile for Diagnosing Pancreatic Duct and Biliary Tract Strictures ［J］. Diagnostics （Basel）， 2022， 12（11）：2704. doi:10.3390/diagnostics12112704 |
| 7 | LEVINK I J M， VISSER I J， KOOPMANN B D M， et al. Protein biomarkers in pancreatic juice and serum for identification of pancreatic cancer ［J］. Gastrointest Endosc， 2022， 96（5）： 801-813. e2. doi:10.1016/j.gie.2022.04.1342 |
| 8 | SAGAMI R， NAKAHODO J， MINAMI R， et al. True diagnostic ability of EUS-guided fine-needle aspiration/biopsy sampling for small pancreatic lesions </=10 mm and salvage diagnosis by pancreatic juice cytology： A multicenter study ［J］. Gastrointest Endosc， 2024， 99（1）： 73-80. doi:10.1016/j.gie.2023.08.006 |
| 9 | LEVINK I J M， JANSEN M， AZMANI Z， et al. Mutation Analysis of Pancreatic Juice and Plasma for the Detection of Pancreatic Cancer ［J］. Int J Mol Sci， 2023， 24（17）：13116. doi:10.3390/ijms241713116 |
| 10 | MATEOS R N， NAKAGAWA H， HIRONO S， et al. Genomic analysis of pancreatic juice DNA assesses malignant risk of intraductal papillary mucinous neoplasm of pancreas ［J］. Cancer Medicine， 2019， 8（10）： 4565-4573. doi:10.1002/cam4.2340 |
| 11 | YOKODE M， AKITA M， FUJIKURA K， et al. High-grade PanIN presenting with localised stricture of the main pancreatic duct： A clinicopathological and molecular study of 10 cases suggests a clue for the early detection of pancreatic cancer ［J］. Histopathology， 2018， 73（2）： 247-258. doi:10.1111/his.13629 |
| 12 | ESHLEMAN J R， NORRIS A L， SADAKARI Y， et al. KRAS and guanine nucleotide-binding protein mutations in pancreatic juice collected from the duodenum of patients at high risk for neoplasia undergoing endoscopic ultrasound ［J］. Clin Gastroenterol Hepatol， 2015， 13（5）： 963-969. e4. doi:10.1016/j.cgh.2014.11.028 |
| 13 | OKADA T， IWANO H， ONO Y， et al. Utility of "liquid biopsy" using pancreatic juice for early detection of pancreatic cancer ［J］. Endosc Int Open， 2018， 6（12）： E1454-E1461. doi:10.1055/a-0721-1747 |
| 14 | SUENAGA M， YU J， SHINDO K， et al. Pancreatic Juice Mutation Concentrations Can Help Predict the Grade of Dysplasia in Patients Undergoing Pancreatic Surveillance ［J］. Clin Cancer Res， 2018， 24（12）： 2963-2974. doi:10.1158/1078-0432.ccr-17-2463 |
| 15 | LU J J， YUAN Z. Application of DNA methylation in early diagnosis and treatment of pancreatic cancer ［J］. World Chinese J Digestol， 2019， 27（1）： 13-19. doi:10.11569/wcjd.v27.i1.13 |
| 16 | MAJUMDER S， RAIMONDO M， TAYLOR W R， et al. Methylated DNA in Pancreatic Juice Distinguishes Patients With Pancreatic Cancer From Controls ［J］. Clin Gastroenterol Hepatol， 2020， 18（3）： 676-683. e3. doi:10.1016/j.cgh.2019.07.017 |
| 17 | NISHIZAWA N， HARADA H， KUMAMOTO Y， et al. Diagnostic potential of hypermethylation of the cysteine dioxygenase 1 gene （CDO1） promoter DNA in pancreatic cancer ［J］. Cancer Sci， 2019， 110（9）： 2846-2855. doi:10.1111/cas.14134 |
| 18 | FUJIYAMA Y， KUMAMOTO Y， NISHIZAWA N， et al. Promoter DNA Hypermethylation of the Cysteine Dioxygenase 1 （CDO1） Gene in Intraductal Papillary Mucinous Neoplasm （IPMN） ［J］. Ann Surg Oncol， 2020， 27（10）： 4007-4016. doi:10.1245/s10434-020-08291-2 |
| 19 | HATA T， MIZUMA M， KUSAKABE T， et al. Simultaneous and sequential combination of genetic and epigenetic biomarkers for the presence of high-grade dysplasia in patients with pancreatic cyst： Discovery in cyst fluid and test in pancreatic juice ［J］. Pancreatology， 2023， 23（2）： 218-226. doi:10.1016/j.pan.2023.01.006 |
| 20 | 周莉， 胡青青， 张银. 胰液在鉴别诊断良恶性IPMN中的应用［J］. 中华胰腺病杂志， 2022， 22（3）： 227-230. |
| 21 | HAYAKAWA H， FUKASAWA M， SATO T， et al. Carcinoembryonic antigen level in the pancreatic juice is effective in malignancy diagnosis and prediction of future malignant transformation of intraductal papillary mucinous neoplasm of the pancreas ［J］. J Gastroenterol， 2019， 54（11）： 1029-1037. doi:10.1007/s00535-019-01592-8 |
| 22 | FUJITA Y， HIRONO S， KAWAI M， et al. Malignant potential and specific characteristics of pure main duct type intraductal papillary mucinous neoplasm ［J］. Eur J Surg Oncol， 2022， 48（5）： 1054-1061. doi:10.1016/j.ejso.2021.11.137 |
| 23 | BRUGGE W R， LEWANDROWSKI K， LEE-LEWANDROW-SKI E， et al. Diagnosis of pancreatic cystic neoplasms： A report of the cooperative pancreatic cyst study ［J］. Gastroenterology， 2004， 126（5）： 1330-1336. doi:10.1053/j.gastro.2004.02.013 |
| 24 | FANG D， ZHANG C， XU P， et al. S100A16 promotes metastasis and progression of pancreatic cancer through FGF19-mediated AKT and ERK1/2 pathways ［J］. Cell Biol Toxicol， 2021， 37（4）： 555-571. doi:10.1007/s10565-020-09574-w |
| 25 | ZHUANG H， CHEN X， DONG F， et al. Prognostic values and immune suppression of the S100A family in pancreatic cancer ［J］. J Cell Mol Med， 2021， 25（6）： 3006-3018. doi:10.1111/jcmm.16343 |
| 26 | MATSUNAGA T， OHTSUKA T， ASANO K， et al. S100P in Duodenal Fluid Is a Useful Diagnostic Marker for Pancreatic Ductal Adenocarcinoma ［J］. Pancreas， 2017， 46（10）： 1288-1295. doi:10.1097/mpa.0000000000000940 |
| 27 | LV J， LIU Y， MO S， et al. Gasdermin E mediates resistance of pancreatic adenocarcinoma to enzymatic digestion through a YBX1-mucin pathway ［J］. Nat Cell Biol， 2022， 24（3）： 364-372. doi:10.1038/s41556-022-00857-4 |
| 28 | TANAKA M， HECKLER M， LIU B， et al. Cytologic Analysis of Pancreatic Juice Increases Specificity of Detection of Malignant IPMN-A Systematic Review ［J］. Clin Gastroenterol Hepatol， 2019， 17（11）： 2199-2211. e21. doi:10.1016/j.cgh.2018.12.034 |
| 29 | SADAKARI Y， OHTSUKA T， OHUCHIDA K， et al. MicroRNA Expression Analyses in Preoperative Pancreatic Juice Samples of Pancreatic Ductal Adenocarcinoma ［J］. JOP， 2010， 11（6）： 587-592. |
| 30 | KURATOMI N， TAKANO S， FUKASAWA M， et al. MiR-10a in Pancreatic Juice as a Biomarker for Invasive Intraductal Papillary Mucinous Neoplasm by miRNA Sequencing ［J］. Int J Mol Sci， 2021， 22（6）：3221. doi:10.3390/ijms22063221 |
| 31 | WANG J， RAIMONDO M， GUHA S， et al. Circulating microRNAs in Pancreatic Juice as Candidate Biomarkers of Pancreatic Cancer ［J］. J Cancer， 2014， 5（8）： 696-705. doi:10.7150/jca.10094 |
| 32 | ZHAO Z， ZHAO G， YANG S， et al. The significance of exosomal RNAs in the development， diagnosis， and treatment of pancreatic cancer ［J］. Cancer Cell Int， 2021， 21（1）： 364. doi:10.1186/s12935-021-02059-8 |
| 33 | HSU S K， JADHAO M， LIAO W T， et al. The Role of Exosomes in Pancreatic Ductal Adenocarcinoma Progression and Their Potential as Biomarkers ［J］. Cancers （Basel）， 2023， 15（6）：1776. doi:10.3390/cancers15061776 |
| 34 | NAKAMURA S， SADAKARI Y， OHTSUKA T， et al. Pancreatic Juice Exosomal MicroRNAs as Biomarkers for Detection of Pancreatic Ductal Adenocarcinoma ［J］. Ann Surg Oncol， 2019， 26（7）： 2104-2111. doi:10.1245/s10434-019-07269-z |
| 35 | ALLENSON K， CASTILLO J， LUCAS F A SAN， et al. High prevalence of mutant KRAS in circulating exosome-derived DNA from early-stage pancreatic cancer patients ［J］. Ann Oncol， 2017， 28（4）： 741-747. doi:10.1093/annonc/mdx004 |
| 36 | NESTERUK K， LEVINK I J M， DE VRIES E， et al. Extracellular vesicle-derived microRNAs in pancreatic juice as biomarkers for detection of pancreatic ductal adenocarcinoma ［J］. Pancreatology， 2022， 22（5）： 626-635. doi:10.1016/j.pan.2022.04.010 |
/
| 〈 |
|
〉 |